Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | ESR1 | P03372 | 4/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.67 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isonicotinic Acid Pentyl Ester SCHEMBL1645891 | 0.95 | LMNA (0.66) | LMNAESR1CYP1A2CYP2C19TSHR | |
| SCHEMBL29067686 | 0.93 | LMNA (0.68) | LMNAESR1CYP1A2CYP2C19TSHR | |
| Isonicotinic Acid Octyl Ester SCHEMBL31313536 | 0.93 | LMNA (0.68) | LMNAESR1CYP1A2CYP2C19TSHR | |
| SCHEMBL1499927 | 0.93 | LMNA (0.68) | LMNAESR1CYP1A2CYP2C19TSHR | |
| Isonicotinic Acid Octadecyl Ester SCHEMBL3128513 | 0.93 | LMNA (0.68) | LMNAESR1CYP1A2CYP2C19TSHR | |
| Isonicotinic Acid Hexyl Ester SCHEMBL4951158 | 0.93 | LMNA (0.68) | LMNAESR1CYP1A2CYP2C19TSHR | |
| SCHEMBL13610196 | 0.93 | LMNA (0.68) | LMNAESR1CYP1A2CYP2C19TSHR | |
| SCHEMBL10780701 | 0.93 | LMNA (0.68) | LMNAESR1CYP1A2CYP2C19TSHR | |
| N-Decyl Isonicotinate SCHEMBL4957558 | 0.93 | LMNA (0.68) | LMNAESR1CYP1A2CYP2C19TSHR | |
| N-Propyl Isonicotinate SCHEMBL4951536 | 0.89 | LMNA (0.67) | LMNAESR1CYP1A2CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | claimed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | claimed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0416804-B1 | EXTERNAL PREPARATION CONTAINING AMUSULOSIN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-05-26 | — | — | EP | claimed |
| EP-0416804-A1 | External preparation containing amusulosin | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1991-03-13 | — | — | EP | claimed |
| US-20090137811-A1 | PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL | PLIVA HRVATSKA D.O.O | 2009-05-28 | — | — | US | disclosed |
| EP-1992616-A1 | Process for the preparation of donepezil and intermediate compounds thereof as well as hydrates of donepezil | Pliva Hrvastka D.O.O. (HR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1910291-A1 | PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL | Pliva-Istrazivanje I Razvoj D.D.O. (HR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007015052-A1 | PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL | PLIVA ISTRAZIVANJE I RAZVOJ D.O.O. (HR) | 2007-02-08 | — | — | WO | disclosed |
| US-5939568-A | Accelerated catalysis of olefinic epoxidations | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998033786-A9 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | — | 1998-12-30 | — | — | WO | disclosed |
| WO-1998033786-A1 | ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-06 | — | — | WO | disclosed |
| US-4847260-A | NICOTINIC AND ISONITINIC ESTER ANTIARRHYTHMIA AGENTS FOR SKINS | NITTO DENKO CORPORATION (JP) | 1989-07-11 | — | — | US | disclosed |
| EP-0267794-A2 | Process for preparing polyolefins | Nippon Petrochemicals Co., Ltd. (JP) | 1988-05-18 | — | — | EP | disclosed |
| US-4631339-A | 1,3,5-triazepinones | ELI LILLY AND COMPANY (US) | 1986-12-23 | — | — | US | disclosed |
| US-4525555-A | TITANIUM COMPOUND SUPPORTED ON SOLID REACTION PRODUCT OF MAGNESIUM HALIDE, SILOXANES, ORGANIC COMPOUNDS | NIPPON OIL COMPANY, LIMITED (JP) | 1985-06-25 | — | — | US | disclosed |
| US-4514564-A | 7β-(2'-(1\",3\",5\"-Triazepin-4\"-one)-2'-(oxime ether)-acetamido)-3-substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| US-4436912-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
| US-4430499-A | 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
| US-4128651-A | Bis-quaternary pyridinium-2-aldoxime salts and a process for their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137811-A1 | PROCESS FOR THE PREPARATION OF DONEPEZIL AND INTERMEDIATE COMPOUNDS THEREOF AS WELL AS HYDRATES OF DONEPEZIL | ACHE, BCHE, WIZ | LMNA 2715/4885ESR1 4604/4885CYP1A2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.